Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells

  1. Bente Benedict
  2. Tanja van Harn
  3. Marleen Dekker
  4. Simone Hermsen
  5. Asli Kucukosmanoglu
  6. Wietske Pieters
  7. Elly Delzenne-Goette
  8. Josephine C Dorsman
  9. Eva Petermann
  10. Floris Foijer
  11. Hein te Riele  Is a corresponding author
  1. The Netherlands Cancer Institute, Netherlands
  2. VU University Medical Center, Netherlands
  3. University of Birmingham, United Kingdom
  4. University Medical Center Groningen, Netherlands

Abstract

In cancer cells, loss of G1/S control is often accompanied by p53 pathway inactivation, the latter usually rationalized as a necessity for suppressing cell cycle arrest and apoptosis. However, we found an unanticipated effect of p53 loss in mouse and human G1-checkpoint-deficient cells: reduction of DNA damage. We show that abrogation of the G1/S-checkpoint allowed cells to enter S-phase under growth-restricting conditions at the expense of severe replication stress manifesting as decelerated DNA replication, reduced origin firing and accumulation of DNA double-strand breaks (DSBs). In this system, loss of p53 allowed mitogen-independent proliferation, not by suppressing apoptosis, but rather by restoring origin firing and reducing DNA breakage. Loss of G1/S control also caused DNA damage and activation of p53 in an in vivo retinoblastoma model. Moreover, in a teratoma model, loss of Trp53 reduced DNA breakage. Thus, loss of p53 may promote growth of incipient cancer cells by reducing replication-stress-induced DNA damage.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Bente Benedict

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  2. Tanja van Harn

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  3. Marleen Dekker

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  4. Simone Hermsen

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  5. Asli Kucukosmanoglu

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  6. Wietske Pieters

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  7. Elly Delzenne-Goette

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  8. Josephine C Dorsman

    Department of Clinical Genetics, VU University Medical Center, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  9. Eva Petermann

    School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Floris Foijer

    European Research Institute for the Biology of Ageing, University Medical Center Groningen, Groningen, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0989-3127
  11. Hein te Riele

    Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, Netherlands
    For correspondence
    h.t.riele@nki.nl
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0255-4042

Funding

KWF Kankerbestrijding (2007-3790)

  • Tanja van Harn
  • Asli Kucukosmanoglu

European Molecular Biology Organization (194-2011)

  • Tanja van Harn

KWF Kankerbestrijding (2014-6702)

  • Bente Benedict

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments involving animals comply with local and international regulations and ethical guidelines (protocol 12026) and have been authorized by the local experimental animal ethical committee at the Netherlands Cancer Institure (DEC-NKI).

Copyright

© 2018, Benedict et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,170
    views
  • 839
    downloads
  • 36
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Bente Benedict
  2. Tanja van Harn
  3. Marleen Dekker
  4. Simone Hermsen
  5. Asli Kucukosmanoglu
  6. Wietske Pieters
  7. Elly Delzenne-Goette
  8. Josephine C Dorsman
  9. Eva Petermann
  10. Floris Foijer
  11. Hein te Riele
(2018)
Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells
eLife 7:e37868.
https://doi.org/10.7554/eLife.37868

Share this article

https://doi.org/10.7554/eLife.37868

Further reading

    1. Cancer Biology
    Han V Han, Richard Efem ... Richard Z Lin
    Research Article

    Most human pancreatic ductal adenocarcinoma (PDAC) are not infiltrated with cytotoxic T cells and are highly resistant to immunotherapy. Over 90% of PDAC have oncogenic KRAS mutations, and phosphoinositide 3-kinases (PI3Ks) are direct effectors of KRAS. Our previous study demonstrated that ablation of Pik3ca in KPC (KrasG12D; Trp53R172H; Pdx1-Cre) pancreatic cancer cells induced host T cells to infiltrate and completely eliminate the tumors in a syngeneic orthotopic implantation mouse model. Now, we show that implantation of Pik3ca−/− KPC (named αKO) cancer cells induces clonal enrichment of cytotoxic T cells infiltrating the pancreatic tumors. To identify potential molecules that can regulate the activity of these anti-tumor T cells, we conducted an in vivo genome-wide gene-deletion screen using αKO cells implanted in the mouse pancreas. The result shows that deletion of propionyl-CoA carboxylase subunit B gene (Pccb) in αKO cells (named p-αKO) leads to immune evasion, tumor progression, and death of host mice. Surprisingly, p-αKO tumors are still infiltrated with clonally enriched CD8+ T cells but they are inactive against tumor cells. However, blockade of PD-L1/PD1 interaction reactivated these clonally enriched T cells infiltrating p-αKO tumors, leading to slower tumor progression and improve survival of host mice. These results indicate that Pccb can modulate the activity of cytotoxic T cells infiltrating some pancreatic cancers and this understanding may lead to improvement in immunotherapy for this difficult-to-treat cancer.

    1. Cancer Biology
    2. Immunology and Inflammation
    Almudena Mendez-Perez, Andres M Acosta-Moreno ... Esteban Veiga
    Short Report

    In this study, we present a proof-of-concept classical vaccination experiment that validates the in silico identification of tumor neoantigens (TNAs) using a machine learning-based platform called NAP-CNB. Unlike other TNA predictors, NAP-CNB leverages RNA-seq data to consider the relative expression of neoantigens in tumors. Our experiments show the efficacy of NAP-CNB. Predicted TNAs elicited potent antitumor responses in mice following classical vaccination protocols. Notably, optimal antitumor activity was observed when targeting the antigen with higher expression in the tumor, which was not the most immunogenic. Additionally, the vaccination combining different neoantigens resulted in vastly improved responses compared to each one individually, showing the worth of multiantigen-based approaches. These findings validate NAP-CNB as an innovative TNA identification platform and make a substantial contribution to advancing the next generation of personalized immunotherapies.